Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...
General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new ...
A Wednesday night earnings report left big questions about how the spending reductions would affect the company.
At the Advances in Genome Biology and Technology, AGBT, General Meeting, 10x Genomics (TXG) announced a series of new product innovations to ...
Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million. On the other hand, the company’s full-year revenue guidance of $620 million ...
Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research ...
Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...
Revenue Guidance (2025): $610 million to $630 million, representing 0% to 3% growth over 2024. 10x Genomics Inc (NASDAQ:TXG) launched major new products across all three platforms, receiving a ...
TD Cowen analyst Dan Brennan lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps a Hold rating on the shares. The ...
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...
PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial ...